加载中
AMEXHealthcareBiotechnology
最新数据
US$0.9476
+US$0.0097 · +1.03%
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
前收盘价
US$0.9476
+US$0.0097 · +1.03%
盘前
US$0.94
−US$0.0076 · -0.80%
10月8日 8:55 ET
盘中时间采用ET。市场数据可能有所延迟。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日内区间
当前US$0.9476
52周区间
当前US$0.9476
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
60
合理估值
情绪
53
多空交织
风险
61
高风险
动量
28
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日内区间
当前US$0.9476
52周区间
当前US$0.9476
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1455.6万 USD | 949.9万 USD | 894.5万 USD | 1470.3万 USD | 389.6万 USD |
| 销货成本 | 84.5万 USD | 33.4万 USD | 67.1万 USD | 72.8万 USD | 142.6万 USD |
| 毛利 | 1371.1万 USD | 916.5万 USD | 827.4万 USD | 1397.5万 USD | 247万 USD |
| 研究与开发 | 1772.9万 USD | 1247.2万 USD | 1570.5万 USD | 1398.7万 USD | 3391.4万 USD |
| 销售、一般及管理费用 | 1846万 USD | 1817.1万 USD | 1730.2万 USD | 2250.8万 USD | 1821.2万 USD |
| 营业费用 | 3549万 USD | 3064.3万 USD | 3300.7万 USD | 3649.5万 USD | 5168.1万 USD |
| 利息收入 | 169.1万 USD | 171.5万 USD | 162.9万 USD | 82.9万 USD | 2000 USD |
| 折旧和摊销 | 69.9万 USD | 60.9万 USD | 69.2万 USD | 72.7万 USD | 87.3万 USD |
| 营业利润 | −2177.9万 USD | −2147.8万 USD | −2473.3万 USD | −2252万 USD | −4921.1万 USD |
| 净利润 | −6353.3万 USD | −1860.9万 USD | −2148.6万 USD | −2627.3万 USD | −4301.9万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2003年12月15日 | US$0.08Irregular | — | — |
除息 2003年12月15日
US$0.08
Irregular
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI649.81万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM426.43万0.01%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF322.93万0.00%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO163.98万0.01%142.49亿 USD0.24%US$355.37-1.43%
iShares Biotechnology ETFIBB132.81万0.01%104.01亿 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO116.32万0.01%180亿 USD0.06%US$112.21-1.26%
iShares Micro-Cap ETFIWC54.15万0.04%13.33亿 USD0.60%US$183.36-1.09%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC22.82万0.02%10.53亿 USD0.20%US$85.79-1.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
